WO2026114301 - KRAS INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/114301
Publication Date
04.06.2026
International Application No.
PCT/CN2025/138031
International Filing Date
27.11.2025
Title **
[English]
KRAS INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
[French]
COMPOSÉ INHIBITEUR DE KRAS, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉES
[Chinese]
KRAS抑制剂化合物、其药物组合物及其用途
Applicants **
SUNSHINE LAKE PHARMA CO., LTD.
Inventors
XIE, Hongming
LI, Chao
TAN, Min
HU, Yangxiao
ZHANG, Yingjun
Priority Data
202411723605.3
28.11.2024
CN
202511537766.8
27.10.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2416 | |
| EPO | Filing, Examination, Granting | 15727 | |
| Japan | Filing, Examination, Granting | 2298 | |
| South Korea | Filing, Examination, Granting | 2409 | |
| USA | Filing, Examination, Granting | 5190 |
Total:
28,040
Contact Us
Abstract[English]
The present invention relates to the technical field of drugs, and relates to a KRAS inhibitor compound, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to a compound represented by formula (I), or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound represented by formula (I). The present invention relates to the compound and the pharmaceutical composition thereof, as well as a use of the compound and the pharmaceutical composition thereof in the preparation of a drug for preventing or treating KRAS-mediated related diseases, especially in the preparation of a drug for preventing or treating cancers.[French]
La présente invention relève du domaine technique des médicaments, et concerne un composé inhibiteur de KRAS, une composition pharmaceutique et une utilisation associées. Plus particulièrement, la présente invention concerne un composé représenté par la formule (I), ou un stéréoisomère, un tautomère, un oxyde d'azote, un solvate, un métabolite, un sel pharmaceutiquement acceptable ou un promédicament du composé représenté par la formule (I). La présente invention concerne le composé et la composition pharmaceutique de celui-ci, ainsi qu'une utilisation du composé et de la composition pharmaceutique de celui-ci dans la préparation d'un médicament pour la prévention ou le traitement de maladies associées à médiation par KRAS, en particulier dans la préparation d'un médicament pour la prévention ou le traitement de cancers.[Chinese]
本发明属于药物技术领域，涉及一种KRAS抑制剂化合物，其药物组合物及其用途。具体地，本发明涉及式(I)所示的化合物、或式(I)所示化合物的立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或前药。本发明所述化合物、其药物组合物，以及该类化合物及其药物组合物在制备用于预防或治疗由KRAS介导的相关疾病的药物中的用途，尤其可用于制备用于预防或治疗癌症的药物。